Acute aortic regurgitation medical therapy: Difference between revisions
| Line 25: | Line 25: | ||
* Administer [[dobutamine]] 0.5 υg/kg/min IV (max 20 υg/kg/min) | * Administer [[dobutamine]] 0.5 υg/kg/min IV (max 20 υg/kg/min) | ||
* Titrate to maintain [[mean arterial pressure]] (MAP) > 60 mmHg | * Titrate to maintain [[mean arterial pressure]] (MAP) > 60 mmHg | ||
* Administer [[beta blocker]]s in | :* Administer [[beta blocker]]s in the setting of [[aortic dissection]] and no evidence of [[cardiogenic shock]] due to blocking the compensatory [[tachycardia]]. <ref name="pmid18628928">{{cite journal |vauthors=Roberts WC, Ko JM |title=Some observations on mitral and aortic valve disease |journal=Proc (Bayl Univ Med Cent) |volume=21 |issue=3 |pages=282–99 |date=July 2008 |pmid=18628928 |pmc=2446420 |doi=10.1080/08998280.2008.11928412 |url=}}</ref> | ||
==Therapeutic Options== | ==Therapeutic Options== | ||
Revision as of 13:38, 21 July 2022
 |
Resident Survival Guide |
|
Aortic Regurgitation Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Acute Aortic regurgitation |
|
Chronic Aortic regurgitation |
|
Special Scenarios |
|
Case Studies |
|
Acute aortic regurgitation medical therapy On the Web |
|
American Roentgen Ray Society Images of Acute aortic regurgitation medical therapy |
|
Risk calculators and risk factors for Acute aortic regurgitation medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S; Usama Talib, BSc, MD [2]
Overview
In patients with acute severe AR resulting from infectious endocarditis or aortic dissection, reduction LV afterload by medications may be a temporary stabilization, but surgery should not be delayed, especially in the presence of hypotension, pulmonary edema, or evidence of low flow. Intra-aortic balloon counterpulsation is contraindicated in patients with acute severe AR. Beta blockers are often used in treating aortic dissection. However, these agents should be used very cautiously because of block the compensatory tachycardia and reduction in blood pressure.
Medical Therapy
In case cardiogenic shock is present in a patient with acute AR, resuscitation measures should be initiated immediately:[1]
- Secure airway [2]
- Administer oxygen[3]
- Secure wide bore intravenous access
- Perform ECG monitor
- Monitor vitals continuously
- Admit to ICU
Medical therapy to treat cardiogenic shock should be immediately initiated:[4]
- Administer nitroprusside 0.3-0.5 υg/kg/min IV (max 10 υg/kg/min), AND
- Administer dobutamine 0.5 υg/kg/min IV (max 20 υg/kg/min)
- Titrate to maintain mean arterial pressure (MAP) > 60 mmHg
- Administer beta blockers in the setting of aortic dissection and no evidence of cardiogenic shock due to blocking the compensatory tachycardia. [5]
Therapeutic Options
Nitroprusside
Nitroprusside lowers afterload and thereby reduces retrograde flow and left ventricular end diastolic pressure.[6]
Inotropic Agents
Inotropic agents such as dopamine and dobutamine can be used to increase the contractility of the heart resulting in improved forward flow.[7]
Beta Blockers
Beta blockers which are often used in managing aortic dissection should be used very cautiously in the presence of acute AR as beta blockers can block the compensatory tachycardia and worsen the cardiac output.[6]
Intraaortic Balloon Pump
Insertion of an intraaortic balloon pump is contraindicated in acute AR, as it may worsen the severity of the regurgitation.[8]
Reference
- ↑ Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP; et al. (2009). "Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice". Eur J Echocardiogr. 10 (1): 1–25. doi:10.1093/ejechocard/jen303. PMID 19065003.
- ↑ Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, Kvols LK (April 1993). "Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients". Circulation. 87 (4): 1188–96. doi:10.1161/01.cir.87.4.1188. PMID 7681733.
- ↑ Gur AK, Odabasi D, Kunt AG, Kunt AS (July 2014). "Isolated tricuspid valve repair for Libman-Sacks endocarditis". Echocardiography. 31 (6): E166–8. doi:10.1111/echo.12558. PMID 24661289.
- ↑ Muraru D, Badano LP, Sarais C, Soldà E, Iliceto S (June 2011). "Evaluation of tricuspid valve morphology and function by transthoracic three-dimensional echocardiography". Curr Cardiol Rep. 13 (3): 242–9. doi:10.1007/s11886-011-0176-3. PMID 21365261.
- ↑ Roberts WC, Ko JM (July 2008). "Some observations on mitral and aortic valve disease". Proc (Bayl Univ Med Cent). 21 (3): 282–99. doi:10.1080/08998280.2008.11928412. PMC 2446420. PMID 18628928.
- ↑ 6.0 6.1 Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 63 (22): e57–185. doi:10.1016/j.jacc.2014.02.536. PMID 24603191.
- ↑ Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Retrieved 2011-04-07. Unknown parameter
|month=ignored (help) - ↑ Rius JB, Mercè AS, del Blanco BG, Aguasca GM, Mas PT, García-Dorado García D (2011). "Resolution of shock-induced aortic regurgitation with an intraaortic balloon pump". Circulation. 124 (4): e131. doi:10.1161/CIRCULATIONAHA.111.038653. PMID 21788594.